Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

NextGen Voices: Quality mentoring.

Segal L, Agarwal D, Isaacson KJ, Oehmke TB, Kumar B, Chen JS, Cusimano JM, Negi S, Tiper I, Bakermans AJ, Jensen MM, Sanganyado E, Zaidi SS, Romero-Molina C, Martínez SE, Anderson SM, Santos GM, De Lella Ezcurra AL, Farragher J, Sharma V, Duncan G, Dutton-Regester K, Kim SA, Yu S, Schwendimann BA, Reichardt JKV, Halder A, Dennis AF, Ellwanger JH, Chiu YH, Kerman BE.

Science. 2018 Oct 5;362(6410):22-24. doi: 10.1126/science.aav5914. No abstract available.

PMID:
30287645
2.

Reflections of a Biomedical Scientist on Four Continents in Interdisciplinary Research.

Reichardt JKV.

Trends Genet. 2018 Jun;34(6):401-403. doi: 10.1016/j.tig.2018.03.004. Epub 2018 Apr 7. No abstract available.

PMID:
29636189
3.

Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Tang L, Platek ME, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JKV, Santella RM, Hsing A, Figg WD, Lippman SM, Thompson IM, Ambrosone CB.

Carcinogenesis. 2018 Feb 9;39(2):125-133. doi: 10.1093/carcin/bgx144.

PMID:
29228205
4.

Genomic Medicine Without Borders: Which Strategies Should Developing Countries Employ to Invest in Precision Medicine? A New "Fast-Second Winner" Strategy.

Mitropoulos K, Cooper DN, Mitropoulou C, Agathos S, Reichardt JKV, Al-Maskari F, Chantratita W, Wonkam A, Dandara C, Katsila T, Lopez-Correa C, Ali BR, Patrinos GP.

OMICS. 2017 Nov;21(11):647-657. doi: 10.1089/omi.2017.0141.

PMID:
29140767
5.

Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems.

Toren A, Pismenyuk T, Yalon M, Freedman S, Simon AJ, Fisher T, Moshe I, Reichardt JK, Constantini S, Mardor Y, Last D, Guez D, Daniels D, Assoulin M, Mehrian-Shai R.

Oncotarget. 2016 Nov 15;7(46):74860-74871. doi: 10.18632/oncotarget.11382.

6.

Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the Prostate Cancer Prevention Trial.

Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, Tangen CM, Thompson IM, Reichardt JK, Figg WD.

Cancer. 2016 Aug 1;122(15):2332-40. doi: 10.1002/cncr.30071. Epub 2016 May 10.

7.

Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis.

Mehrian-Shai R, Yalon M, Moshe I, Barshack I, Nass D, Jacob J, Dor C, Reichardt JK, Constantini S, Toren A.

BMC Genomics. 2016 Jan 14;17:56. doi: 10.1186/s12864-016-2370-6.

8.

Serum androgens and prostate cancer risk: results from the placebo arm of the Prostate Cancer Prevention Trial.

Schenk JM, Till C, Hsing AW, Stanczyk FZ, Gong Z, Neuhouser ML, Reichardt JK, Hoque AM, Figg WD, Goodman PJ, Tangen CM, Thompson IM.

Cancer Causes Control. 2016 Feb;27(2):175-82. doi: 10.1007/s10552-015-0695-0. Epub 2015 Nov 20.

9.

Genomics is changing personal healthcare and medicine: the dawn of iPH (individualized preventive healthcare).

Mehrian-Shai R, Reichardt JK.

Hum Genomics. 2015 Nov 4;9:29. doi: 10.1186/s40246-015-0052-0.

10.

Schwannomas exhibit distinct size-dependent gene-expression patterns.

Mehrian-Shai R, Freedman S, Shams S, Doherty J, Slattery W, Hsu NY, Reichardt JK, Andalibi A, Toren A.

Future Oncol. 2015;11(12):1751-8. doi: 10.2217/fon.15.72.

PMID:
26075443
11.

Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Chau CH, Price DK, Till C, Goodman PJ, Chen X, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Tangen CM, Chu L, Parnes HL, Schenk JM, Reichardt JK, Thompson IM, Figg WD.

PLoS One. 2015 May 8;10(5):e0126672. doi: 10.1371/journal.pone.0126672. eCollection 2015.

12.

Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease.

Hoque A, Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, vanBokhoven A, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Ambrosone CB, Thompson IM.

Urology. 2015 Mar;85(3):616-20. doi: 10.1016/j.urology.2014.11.024.

13.

Single nucleotide differences (SNDs) continue to contaminate the dbSNP database with consequences for human genomics and health.

Arthur JW, Cheung FS, Reichardt JK.

Hum Mutat. 2015 Feb;36(2):196-9. doi: 10.1002/humu.22735.

PMID:
25421747
14.

Novel age-dependent targets in vestibular schwannomas.

Toren A, Reichardt JK, Andalibi A, Hsu NY, Doherty J, Slattery W, Mehrian-Shai R.

Hum Genomics. 2014 Jun 30;8:10. doi: 10.1186/1479-7364-8-10.

15.

Androgen receptor CAG repeat length and TMPRSS2:ETS prostate cancer risk: results From the Prostate Cancer Prevention Trial.

Figg WD, Chau CH, Price DK, Till C, Goodman PJ, Cho Y, Varella-Garcia M, Reichardt JK, Tangen CM, Leach RJ, van Bokhoven A, Thompson IM, Lucia MS.

Urology. 2014 Jul;84(1):127-31. doi: 10.1016/j.urology.2014.03.015. Epub 2014 May 10.

16.

Translesion DNA polymerases and cancer.

Makridakis NM, Reichardt JK.

Front Genet. 2012 Sep 6;3:174. doi: 10.3389/fgene.2012.00174. eCollection 2012.

17.

Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.

Kristal AR, Till C, Tangen CM, Goodman PJ, Neuhouser ML, Stanczyk FZ, Chu LW, Patel SK, Thompson IM, Reichardt JK, Hoque A, Platz EA, Figg WD, Van Bokhoven A, Lippman SM, Hsing AW.

Cancer Epidemiol Biomarkers Prev. 2012 Oct;21(10):1823-32. doi: 10.1158/1055-9965.EPI-12-0695. Epub 2012 Aug 9.

18.

Current progress in using vitamin D and its analogs for cancer prevention and treatment.

Cheung FS, Lovicu FJ, Reichardt JK.

Expert Rev Anticancer Ther. 2012 Jun;12(6):811-37. doi: 10.1586/era.12.53. Review.

PMID:
22716497
19.

Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.

Tang L, Yao S, Till C, Goodman PJ, Tangen CM, Wu Y, Kristal AR, Platz EA, Neuhouser ML, Stanczyk FZ, Reichardt JK, Santella RM, Hsing A, Hoque A, Lippman SM, Thompson IM, Ambrosone CB.

Carcinogenesis. 2011 Oct;32(10):1500-6. doi: 10.1093/carcin/bgr139. Epub 2011 Jul 18.

20.

Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.

Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, Platz EA, Stanczyk FZ, Reichardt JK, Tang L, Neuhouser ML, Santella RM, Figg WD, Price DK, Parnes HL, Lippman SM, Thompson IM, Ambrosone CB, Hoque A.

Cancer Causes Control. 2011 Aug;22(8):1121-31. doi: 10.1007/s10552-011-9787-7. Epub 2011 Jun 11.

21.

Modeling single nucleotide polymorphisms in the human AKR1C1 and AKR1C2 genes: implications for functional and genotyping analyses.

Arthur JW, Reichardt JK.

PLoS One. 2010 Dec 31;5(12):e15604. doi: 10.1371/journal.pone.0015604.

22.

Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.

Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Lucia MS, Platz EA, Figg WD, Hoque A, Hsing A, Neuhouser ML, Parnes HL, Reichardt JK, Santella RM, Till C, Lippman SM.

Cancer Prev Res (Phila). 2010 Dec;3(12):1523-33. doi: 10.1158/1940-6207.CAPR-09-0256.

23.

Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer.

Hulin-Curtis SL, Petit D, Figg WD, Hsing AW, Reichardt JK.

Future Oncol. 2010 Dec;6(12):1897-913. doi: 10.2217/fon.10.149. Review.

PMID:
21142863
24.

Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Price DK, Chau CH, Till C, Goodman PJ, Baum CE, Ockers SB, English BC, Minasian L, Parnes HL, Hsing AW, Reichardt JK, Hoque A, Tangen CM, Kristal AR, Thompson IM, Figg WD.

J Urol. 2010 Dec;184(6):2297-302. doi: 10.1016/j.juro.2010.08.005. Epub 2010 Oct 16.

25.

Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer.

Das K, Lorena PD, Ng LK, Lim D, Shen L, Siow WY, Teh M, Reichardt JK, Salto-Tellez M.

Endocr Relat Cancer. 2010 Aug 16;17(3):757-70. doi: 10.1677/ERC-10-0022. Print 2010 Sep.

PMID:
20519274
26.

Single nucleotide differences (SNDs) in the dbSNP database may lead to errors in genotyping and haplotyping studies.

Musumeci L, Arthur JW, Cheung FS, Hoque A, Lippman S, Reichardt JK.

Hum Mutat. 2010 Jan;31(1):67-73. doi: 10.1002/humu.21137.

27.

PCR-free method detects high frequency of genomic instability in prostate cancer.

Makridakis NM, Phipps T, Srivastav S, Reichardt JK.

Nucleic Acids Res. 2009 Dec;37(22):7441-6. doi: 10.1093/nar/gkp761.

28.

The role of human demographic history in determining the distribution and frequency of transferase-deficient galactosaemia mutations.

Flanagan JM, McMahon G, Brendan Chia SH, Fitzpatrick P, Tighe O, O'Neill C, Briones P, Gort L, Kozak L, Magee A, Naughten E, Radomyska B, Schwartz M, Shin JS, Strobl WM, Tyfield LA, Waterham HR, Russell H, Bertorelle G, Reichardt JK, Mayne PD, Croke DT.

Heredity (Edinb). 2010 Feb;104(2):148-54. doi: 10.1038/hdy.2009.84. Epub 2009 Jul 29.

29.

The future of the human SNP identification: which individuals to sequence?

Reichardt JK, Mehrian-Shai R.

Proc Natl Acad Sci U S A. 2009 May 12;106(19):E50. doi: 10.1073/pnas.0903681106. Epub 2009 Apr 29. No abstract available.

30.

Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas.

Shai RM, Reichardt JK, Chen TC.

Future Oncol. 2008 Aug;4(4):525-34. doi: 10.2217/14796694.4.4.525. Review.

PMID:
18684063
31.

Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif.

Makridakis NM, Caldas Ferraz LF, Reichardt JK.

Hum Mutat. 2009 Jan;30(1):39-48. doi: 10.1002/humu.20810.

32.

No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.

Pearce CL, Van Den Berg DJ, Makridakis N, Reichardt JK, Ross RK, Pike MC, Kolonel LN, Henderson BE.

Hum Mol Genet. 2008 Aug 15;17(16):2456-61. doi: 10.1093/hmg/ddn145. Epub 2008 May 10.

33.

Androgens and the molecular epidemiology of prostate cancer.

Chu LW, Reichardt JK, Hsing AW.

Curr Opin Endocrinol Diabetes Obes. 2008 Jun;15(3):261-70. doi: 10.1097/MED.0b013e3282febcf6. Review.

PMID:
18438175
34.

Realizing the full potential of the sequenced human genome.

Reichardt JK.

Trends Genet. 2008 May;24(5):219-20. doi: 10.1016/j.tig.2008.03.002. Epub 2008 Mar 28. No abstract available.

PMID:
18375010
35.

Quo vadis, genoma? A call to pipettes for biochemists.

Reichardt JK.

Trends Biochem Sci. 2007 Dec;32(12):529-30. Epub 2007 Nov 5. No abstract available.

PMID:
17980604
36.

Genomic biomarkers, androgen pathway and prostate cancer.

D'Amico F, Biancolella M, Margiotti K, Reichardt JK, Novelli G.

Pharmacogenomics. 2007 Jun;8(6):645-61. Review.

PMID:
17559353
37.
38.

Molecular epidemiology of prostate cancer: hormone-related genetic loci.

Chokkalingam AP, Stanczyk FZ, Reichardt JK, Hsing AW.

Front Biosci. 2007 May 1;12:3436-60. Review.

PMID:
17485312
39.

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer.

Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL.

Proc Natl Acad Sci U S A. 2007 Mar 27;104(13):5563-8. Epub 2007 Mar 19.

40.
41.

Genomics in breast and prostate cancer: assessment of the current state and future perspectives.

Mehrian-Shai R, Reichardt JK.

Future Oncol. 2006 Jun;2(3):357-62. Review.

PMID:
16787115
42.

Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer.

Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK.

Urol Oncol. 2005 Jul-Aug;23(4):246-53.

PMID:
16018939
43.

Androgen metabolic genes in prostate cancer predisposition and progression.

Makridakis NM, Buchanan G, Tilley W, Reichardt JK.

Front Biosci. 2005 Sep 1;10:2892-903. Review.

PMID:
15970543
44.
45.

Robustness of gene expression profiling in glioma specimen samplings and derived cell lines.

Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF.

Brain Res Mol Brain Res. 2005 May 20;136(1-2):99-103.

PMID:
15893592
46.

A renaissance of "biochemical genetics"? SNPs, haplotypes, function, and complex diseases.

Mehrian-Shai R, Reichardt JK.

Mol Genet Metab. 2004 Sep-Oct;83(1-2):47-50. Review.

PMID:
15464419
47.
49.

Pharmacogenetics of human androgens and prostate cancer--an update.

Novelli G, Margiotti K, Chiocca AM, Spera E, Micali F, Reichardt JK.

Pharmacogenomics. 2004 Apr;5(3):283-94. Review.

PMID:
15102543
50.

Molecular epidemiology of androgen-metabolic loci in prostate cancer: predisposition and progression.

Makridakis NM, Reichardt JK.

J Urol. 2004 Feb;171(2 Pt 2):S25-8; discussion S28-9. Review.

PMID:
14713749

Supplemental Content

Loading ...
Support Center